Document:

Exhibit 10.1

 

Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by:
[***]

 

JOINT VENTURE AGREEMENT

PROMIS - BCNI

STAGE ONE: SERVICES

 

This Joint Venture Agreement ( “AGREEMENT”) is entered
into effective July 7, 2020 (the “Effective Date”), by and between ProMIS Neurosciences, Inc., a Canadian corporation with
an address at 1920 Yonge Street, Toronto, ON, M4S 3E2 Canada (“PROMIS”), and BC Neuroimmunology Lab Inc (BCNI)
an accredited, CAP certified diagnostic lab in British Columbia, with an address at UBC Hospital, S157-2211 Wesbrook Mall, Vancouver BC
V6T 2B5 (“BCNI”).

 

RECITALS

 

Whereas ProMIS is a publicly traded (TSX) development stage biotechnology
company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as
Disease Specific Epitopes on the molecular surface of proteins. In the infectious disease setting, these disease-specific epitopes represent
peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence
of antibodies that arise in response to a specific infection, such as COVID-19. These peptide antigens can also be used to create potential
therapeutic antibodies to treat active infection, as well as serve as the basis for development of vaccines. ProMIS’ proprietary
technology platform has created a portfolio of patented or patent pending antibodies and peptide antigens, which can be used as both therapeutics
(antibodies, vaccines, gene therapy) and as reagents in proprietary diagnostic assays.; and

 

Whereas BC Neuroimmunology Lab Inc. (BCNI) is a private full service
clinical neuroimmunology lab located in the University of British Columbia (Vancouver) hospital. BCNI is accredited by both the College
of American Pathologists (CAP) and Diagnostic accreditation program (DAP) at the College of Physicians and Surgeons of BC (CPSBC) following
the ISO15189 guidelines. BCNI is the North American reference center for six high complexity serological immunoassays. BCNI has extensive
experience and expertise in Surface Plasmon Resonance (SPR), live and fixed cell-based assays, radio immunoprecipitation assays, ELISA,
immunoblot, and immunohistochemistry assays in a clinical assay setting, servicing the neurology community in North America and Worldwide.

 

and

 

Whereas PROMIS and BCNI wish to enter into a joint venture business
arrangement to provide the service of highly sensitive and specific serological assays for the detection and characterization (neutralizing
activity for example) of antibodies to the SARS-CoV-2 corona virus that is responsible for COVID-19 , (the “JV SERVICE”).

 

NOW, THEREFORE, in consideration of the mutual covenants and premises
set forth herein, the Parties agree as follows;

 

    

     

    

 

Article
I. DEFINITIONS

 

In this Agreement, unless the context indicates otherwise, the words
and expressions set out below shall have the meanings assigned to them and cognate expressions shall have a corresponding meaning, namely:

 

“Agreement” means this Service Joint Venture Agreement,
together with any validly executed amendments, schedules and appendices.

 

“Applicable Law” means, as to any person, any statute,
law, rule, regulation, administrative guidance, directive, treaty, judgment, order, decree or injunction of any governmental authority
that is applicable to or binding upon such person or any of its properties.

 

“Background Intellectual Property” means any Intellectual
Property excluding Foreground Intellectual Property owned or controlled by either Party prior to commencement of or independently from
the JV SERVICES, and which the owning Party contributes or uses in the course of performing the JV SERVICE

 

“Commercialize” or “Commercialization” includes
the development, distribution, sale, license, transfer or any other venture through which the JV SERVICE or a Party seeks to promote,
market, sell, distribute, manufacture or develop the JV SERVICES, or having any of the foregoing done on its behalf.

 

“Confidential Information” means any information
disclosed by one Party to the other that is not publicly available information, and which is either identified as confidential at the
time of disclosure or which would reasonably be considered to be confidential by its nature or the context of disclosure, including without
limitation Background Intellectual Property disclosed by one Party to the other for use in the JV SERVICES/LICENSED SERVICES and identified
as confidential before or at the time of disclosure, any business information pertaining to a Party or its products or services, and any
products, processes, samples, biological or proprietary materials provided or disclosed pursuant to this Agreement

 

“Definitive Agreements” means such agreements as
may be necessary to set up the JV SERVICE and/or Immusafe Labs Inc. and complete its organization as contemplated herein.

 

“Field” means (i) the development, production and
use of serological assays for the detection and characterization of antibodies to the SARS-CoV-2 corona virus for the screening and monitoring
of subjects with prior exposure to the virus responsible for COVID-19 and for evaluation and monitoring of antibody response following
exposure to vaccine during vaccine development and post marketing follow up.

 

“Foreground Intellectual Property” means any Intellectual
Property which is generated or first reduced to practice by either Party directly as a result of the work undertaken in accordance with
this Agreement, and which is relevant to the JV SERVICE and the Licensed Services/Licensed Technology.

 

    -2-

     

    

 

“Improvement(s)” means any modification, development,
alteration, derivative or technical advance in or relating to the Licensed Technology/Licensed Services which cannot be used or practiced
without infringing the Background Intellectual Property Rights.

 

‘Intellectual Property Rights’ means any and all
existing and future legal protection recognized by law (whether by statute, in equity, at common law or otherwise) anywhere in the world
in respect of the Licensed Technology and Licensed Services, including without limitation trade secret and confidential information protection,
Know-How, patents, Patents, copyright and copyright registration, industrial design registration and trade-marks and trade-mark registrations
and other registrations or grants of rights analogous thereto.

 

“Joint Venture” means the business arrangement between
the Parties as described in this Agreement, including the JV SERVICE and Immusafe Labs Inc..

 

“JV SERVICE” means the service of providing highly
sensitive and specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 corona virus that is
responsible for COVID-19 to pharmaceutical companies/vaccine developers and governmental agencies, using Licensed Services and/or Licensed
Technology, as well as other technology that may be available to the Joint Venture;

 

“Know-how” means all the research results, data,
reports, dossiers, technical information, expertise, practice, experience, skill and technical knowledge of industrial significance and
all unpatented trade secrets, manufacturing methods and technologies, SOP’s, QA and QC procedures, designs, processes, techniques,
information, drawings and specifications, and technical data acquired by and in the possession of PROMIS, BCNI, or JV SERVICE, and not
in the public domain, and relating to the Licensed Technology or Licensed Services.

 

‘Licensed Service(s)’ means any assay that is/are
derived in whole or in part by the use of any of the Intellectual Property Rights and/or the Licensed Technology, of either Party, including
without limitation PROMIS proprietary antigen peptides for development of highly sensitive and specific serological assays for the detection
and characterization of antibodies to the SARS-CoV-2 corona virus that is responsible for COVID-19, as listed in this Agreement or added
to it by validly executed amendment.

 

“Licensed Technology” means the platforms owned
by PROMIS and/or BCNI that will be used by the JV SERVICE and Immusafe Labs Inc. to develop and provide the serological antibody assays,
and any Intellectual Property Rights therein or thereto, necessary or useful to develop, manufacture or Commercialize the Licensed Service(s)
within the Field in the Territory. The Licensed Technology includes, without limitation, the Technology and Patents listed on Appendix
A.

 

“Net Revenue” shall mean Revenue, less such of the
following items but only insofar as they are separately itemized on the invoice and actually paid or allowed: (i) discounts or rebates
(ii) credits or allowances upon claims or returns, (iii) taxes or other government charges, and (iv) shipping and insurance costs, brokerage
and customs duties.

 

“Immusafe Labs Inc.” means the corporate entity
which is established by BCNI and related companies for the purpose to conduct the business and operations of the JV SERVICE.

 

    -3-

     

    

 

“Patents” means those patents and patent applications
listed in, or which may be added to, Appendix A from time to time hereunder, any divisional applications, continuation applications, continuation-in-part
applications, reissues, or re-examinations claiming priority to either of these, and all patent applications and patents corresponding
to or derived from any of the above.

 

“Party” means PROMIS or BCNI, if individually referred
to, and “Parties” shall mean PROMIS and BCNI together.

 

“Revenue” means the gross amount of consideration
received by JV SERVICE or Immusafe Labs Inc., as the case may be, in respect of the provision of the JV SERVICE, including money, goods
and services, royalties, milestone payments and any other consideration that may be received from a Sale of any of the services provided
by the JV SERVICE or Immusafe Labs Inc..

 

“Sale” means any sale, lease, use and services associated
with provision of a JV SERVICE, Licensed Service or service relating to a Licensed Service and “Sales” and “Sell”
have corresponding meanings.

 

“SARS-CoV-2” means the novel coronavirus responsible
for the COVID-19 pandemic.

 

“Technology” includes inventions, discoveries, designs,
ideas, works, creations, developments, algorithms, drawings, compilations of information, analyses experiments, data, reports, Know-How,
formulae, methods, processes, techniques, moulds, prototypes, products, samples, equipment, tools, machines, software and documentation
therefore, flow-charts, specifications and source code listings; and includes any modifications or improvements thereto, whether patentable
or not.

 

“Term” is defined in Section 27.

 

“Territory” is defined in Section 14.

 

Article
II. PURPOSE OF THE JOINT VENTURE

 

Section
2.01.      

 

		(a)	The purpose of this Joint Venture is to establish, and operate the JV SERVICE to provide highly sensitive and specific serological
assays for the detection and characterization of antibodies against the SARS- CoV-2 corona virus that is responsible for COVID-19 to the
medical community, government agencies and pharmaceutical companies/vaccine developers, using Licensed Services and/or Licensed Technology,
as well as other technology that may be available to the Joint Venture;

 

		(b)	The Joint Venture will focus on building the foundation for a revenue base providing (“JV SERVICE”) highly sensitive and
specific serological assays for the detection and characterization of antibodies to the SARS-CoV-2 corona virus.

 

		(c)	The companies shall continue to interact with and seek partnerships with platform diagnostic companies, public healthcare payors,
research institutions, private healthcare payors, national defence organizations and vaccine
developers for revenue expansion.

 

    -4-

     

    

 

		(d)	Conducting clinical validation, developing algorithms to increase prediction accuracy in multiplex assay formats based in Bayesian
Statistics and pursuing regulatory approvals required to develop revenue, if those activities are adequately funded by third parties,
or by mutual consent funded by either or both ProMIS or BCNI; and,

 

		(e)	Pursuing potential collaborations with diagnostic labs outside of BCNI lab, or potentially licensing/partnering deals with platform
companies or global diagnostics players, to develop revenue beyond what the Joint Venture can realize at BCNI.

 

Article
III. BACKGROUND

 

Section
3.01.     Experience of the Parties

 

Both Parties bring significant experience with respect to development
and provision of diagnostic assay services to this Joint Venture.

 

		(a)	Specifically, ProMIS is a development stage biotechnology company whose unique core technology is the ability to rationally predict
the site and shape (conformation) of novel targets known as Disease Specific Epitopes on the molecular surface of proteins. In the infectious
disease setting, these disease-specific epitopes represent peptide antigens that can be used as an essential component to create accurate
and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19.
These peptide antigens can also be used to create potential therapeutic antibodies to treat active infection, as well as serve as the
basis for development of vaccines. ProMIS’ proprietary technology platform has created a portfolio of patented or patent pending
antibodies and peptide antigens, which can be used as both therapeutics (antibodies, vaccines, gene therapy) and as reagents in proprietary
diagnostic assays. ProMIS is also well-connected in the scientific, medical and pharmaceutical communities.

 

		(b)	BCNI is an accredited, ISO and CAP certified diagnostic lab in British Columbia, with expertise and experience in validating and accrediting
assays with ISO and College of American Pathologists. BCNI also has experience in marketing and sales of such assays to the neurologist
community, larger labs with vast distribution, and pharmaceutical companies.

 

Article
IV. CONTRIBUTIONS OF THE PARTIES.

 

The Parties will faithfully dedicate reasonable commercial and technological
resources to help the business of the JV SERVICE succeed.

 

    -5-

     

    

 

Section 4.01.    
Joint Contributions

 

		(a)	The parties expect operating expenses to conduct the evaluation of peptide antigens and improved serologic assays, regular operating
costs, legal costs at the JV/Immusafe and costs to bring the assay through Health Canada and FDA approvals. ProMIS will fund those costs,
with prior notification of planned expenditures, and those accrued costs will be repaid from initial profits, if any, to the JV. BCNI
has spent significant resources, including approximately USD [***] cash, 5-800 hundreds’ of highly qualified worker manhours and
world class expertise (e.g. Dr. Hans Frykman has contributed crucial scientific height) to develop this assay to current excellence and
best in class state. In recognition of this, no further expenses should be expected to be carried by BCNI for the lifetime of this JV
or in Immusafe Labs Inc.

 

		(b)	Major expense projects (such as a vaccine validation clinical trial) are not expected, unless funded by third parties such as global
platform partners, vaccine manufacturers, government agencies, or others.

 

		(c)	Immusafe Labs Inc. was established by BCNI and related companies to provide the JV SERVICE. ProMIS will acquire 50% of the shares
for CAD [***]. Additional non-voting shares in Immusafe Labs Inc. can be sold to familiar and supportive 3rd parties such as ProMIS shareholders
and friends and family of the founders up to value of USD $[***] and at a pre-money value agreeable to BCNI and ProMIS.

 

Section
4.02.     Individual Contributions

 

		(a)	In addition, PROMIS’s contribution to the JV SERVICE will include:

 

		(i)	Provide at cost proprietary antigens and peptides which can be used as reagents in proprietary serological antibody assays for the
JV SERVICE;

 

		(ii)	License to the JV SERVICE its proprietary technology platforms (“Licensed Technology”) to predict better specificity for
diagnostic purposes;

 

		(iii)	Apply its existing proprietary reagents to assay development and will continue develop and contribute new proprietary reagents.

 

		(iv)	Regulatory and development support;

 

		(v)	Take the lead on market related activities, including outreach to KOLs, pharma companies/vaccine developers, government agencies and
other revenue development opportunities and will together with BCNI assign or hire staff in Immusafe Labs Inc. to lead that effort.

 

		(vi)	Continuous scientific, technological, marketing, strategic, updating process development, and support.

 

    -6-

     

    

 

		(b)	In addition, BCNI’s contribution to the JV SERVICE will include:

 

		(i)	General management of the JV SERVICE: Dr. Hans Frykman of BCNI will serve as lab director and initial CEO of Immusafe Labs Inc. at
the Vancouver site with deferred payment until the JV is cashflow positive and can carry his salary, and BCNI will initially hire and
manage capable staff with full pay from Immusafe Labs Inc., and will manage the operations of the accredited laboratories.;

 

		(ii)	Perform all serological assays at cost, calculated by an internal standard method normally used;

 

		(iii)	Provide guidance in marketing and sales of the assays/or JV service to government organizations, public healthcare payors, private
healthcare payors, pharmaceutical companies/vaccine developers;

 

		(iv)	Contribute (at deferred cost as described above) its expertise and experience in validating and accrediting the assays with CPSBC
(DAP) and College of American Pathologists (CAP);

 

		(v)	Assume primary responsibility for dealing with health and regulatory authorities in the Territory, including, without limitation,
presentation, submission and approval of any necessary marketing/regulatory authorizations for the JV SERVICE and Licensed Services.

 

Article
V. ALLOCATION AND DISTRIBUTION OF REVENUES

 

Section
5.01.     Ownership

 

PROMIS and BCNI shall each own 50% of the JV SERVICE and Immusafe Labs
Inc. which has been established by BCNI and related companies to provide the JV SERVICE.

 

Section
5.02.     Revenue

 

Net Revenue from the JV SERVICE will be distributed to each Party equally,
except as otherwise specified in this Agreement. JV SERVICE revenue will be recognized by JV SERVICE/Immusafe Labs Inc.. Direct expenses
associated with that revenue will be covered by that revenue to the extent possible.

 

Section
5.03.     Working Capital, Operating Losses

 

Working capital needs, or operating losses will be covered equally
by both parties.

 

Section
5.04.     Investment Decisions

 

Investment decisions will require mutual consent and will be funded
by ProMIS, or come from current revenue and operating profit.

 

    -7-

     

    

 

Section 5.05.    
Surplus, Operating Cash Flow

 

		(i)	Cash surpluses resulting from assay tests carried out at BCNI lab on behalf of Immusafe Labs Inc., defined as operating cash flow
after paying current expenses and not allocated to capital investment or other costs by mutual consent, will be distributed equally (50/50
split) to both parties on a time schedule to be agreed - not more frequent than monthly, not less frequent than quarterly.

 

		(ii)	The first USD [***] cash surplus generated from labs or partnerships other than BCNI will be distributed equally (50/50 split).

 

		(iii)	Subsequent to generation of the first USD [***] cash surplus as per item (ii) above, net revenue from assays conducted by labs or
partnerships other than BCNI will be distributed equally (50/50 split) if such assays do not incorporate any ProMIS proprietary reagents;
the net revenue from assays conducted by labs or partnerships other than BCNI will be distributed according to an 80/20 split in favor
of ProMIS, if such assays incorporate any ProMIS proprietary reagents.

 

Article
VI. NAME

 

The name of Immusafe Labs Inc. is mutually agreed by PROMIS and BCNI.

 

Article
VII. PRINCIPAL PLACE OF BUSINESS

 

The principal place of business of JV SERVICE/Immusafe Labs Inc. shall
be initially at the BCNI premises in Vancouver, BC, unless PROMIS and BCNI later decide otherwise.

 

Article
VIII. INTELLECTUAL PROPERTY

 

Section
8.01.     Ownership of Intellectual Property Rights

 

		(a)	Background Intellectual Property All Background Intellectual Property including any proprietary materials provided and used
in connection with the JV SERVICE and/or the Licensed Services shall remain the property of the Party introducing the same. Neither Party
will make any representation or do any act which may be taken to indicate that it has any right, title or interest in or to the ownership
or use of any of the Background Intellectual Property of the other party except under the terms of this Agreement. Each Party acknowledges
and confirms that nothing contained in this Agreement shall give it any right, title or interest in or to the Background Intellectual
Property of the other Party save as granted by this Agreement. The Parties agree that any Improvements to a Party’s Background Intellectual
Property arising from the Joint Venture will be deemed to form part of that Party’s Background Intellectual Property.

 

		(b)	Foreground Intellectual Property.

 

    -8-

     

    

 

		(i)	Each Party shall own any Foreground Intellectual Property developed solely by it and shall grant to the JV SERVICE a royalty-free,
perpetual non-exclusive license to such Foreground Intellectual Property that is necessary or useful to the JV SERVICE. Such license shall
be transferable to Immusafe Labs Inc. established by BCNI and related companies to operate the JV SERVICE. The Party owning such Foreground
Intellectual Property shall have the responsibility of registering, maintaining and enforcing any protection for such Foreground Intellectual
Property.

 

		(ii)	Any Foreground Intellectual Property jointly developed in the JV SERVICE prior to ProMIS acquiring 50% ownership in Immusafe Labs
Inc. shall be owned jointly by the Parties, with the intention that such ownership shall be transferred to Immusafe Labs Inc. which is
established by the BCNI and related companies to operate the business of the JV SERVICES. Any IP developed in Immusafe Labs Inc. will
be owned by Immusafe Labs Inc. In the interim, the Parties shall be jointly responsible for registering, maintaining and enforcing any
protection for such Foreground Intellectual Property, and ProMIS bear the costs with the preference to recovering those costs from profits
if any at a future date.

 

Article
IX. LICENSE

 

The JV SERVICE will have the non-exclusive license to use the Licensed
Technology to make, market and sell in the Territory the Licensed Services contemplated by this Agreement. Each Party hereby grants to
the JV SERVICE a royalty-based, non-exclusive license for the duration of the Agreement to use its Background Intellectual Property for
the sole purpose of providing the Licensed Services.

 

Article
X. REPORTS & RECORDS

 

Section
10.01. Reports and Other Deliveries.

 

Within thirty (30) days of the receipt of Revenue in respect of any
services provided by the JV SERVICE, the JV SERVICE shall provide to PROMIS and BCNI a written report detailing any Revenue received in
respect of the JV

 

SERVICE from any source and the amount thereof, and calculating the
payment due to each Party in respect thereof.

 

Section
10.02. Books and Records.

 

The JV SERVICE shall keep complete, true and accurate books of
account containing all particulars that may be necessary for the purpose of showing the amounts payable to PROMIS and BCNI. Such
books of account shall normally be kept at the JV SERVICE’S principal place of business. Upon reasonable notice to the JV
SERVICE during regular working hours, all applicable books and the supporting data shall be available for inspection by PROMIS or
BCNI or their agents, on a confidential basis, at all reasonable times for up to five years following the end of the calendar year
to which they pertain, for the purpose of verifying such JV SERVICE accounting of payments and compliance in other respects with
this Agreement. If such inspection determines that any amount that should have been paid has not been paid, the JV SERVICE shall
promptly pay such amount. If an additional payment is 5% or greater than the amount previously reported and paid for in the relevant
period, then the JV SERVICE shall pay PROMIS/BCNI any such deficiency as well as the expenses of the examination. The cost of
accounting services (initially at BCNI) shall be carried by the JV at cost. Costs for the bookkeeping, records and accounting shall
be carried by the JV or Immusafe Labs Inc. and initially provided at cost to the JV or Immusafe by BCNI staff.

 

    -9-

     

    

 

 

Article
XI. NO VIOLATION OF AGREEMENT DUE TO OTHER ACTIVITIES Subject to any exclusivity provisions set forth in this Agreement,
BCNI acknowledges that PROMIS is involved in research and development projects and agreements which involve the development, manufacturing
and commercialization of biologic products and that this does not infringe this Agreement between BCNI and PROMIS. PROMIS, acknowledge
that BCNI is involved in the research and development, manufacturing and commercialization of diagnostic products primarily but not exclusively
in the field of Neuroimmunology and that this does not infringe this agreement between BCNI and PROMIS.

 

Article
XII. GOVERNANCE AND MANAGEMENT OF JV SERVICE

 

Section
12.01. Lab Director

 

		(a)	In Stage One, Hans Frykman of BCNI will serve as lab director at the Vancouver site, or BCNI will initially hire and manage capable
staff and will manage the operations of the accredited laboratories in Canada. Dr. Hans Frykman will defer his fees for service until
the JV is cash flow positive and when it can carry such cost without forsaking future opportunities. Such professional fees, will at that
time, have preference to paying shareholders or the JV partners. Other staff at BCNI involved in the working for this JV and Immusafe
Labs Inc. will be reimbursed on a monthly basis at cost starting July 10.

 

Section
12.02. Key Decisions

 

		(a)	The Parties will discuss all material decisions affecting the operations, expenditures and commitments of the JV SERVICE, and BCNI
or its designates shall not make any key decisions concerning such operations, expenditures and commitments without the prior written
consent of PROMIS.

 

Article
XIII. TERRITORY

 

The Territory in which the JV SERVICE will operate, and for which the
licenses hereunder are granted is Worldwide

 

    -10-

     

    

 

Article
XIV. TRANSPARENCY

 

Subject to applicable confidentiality provisions and Applicable Laws,
all financial and commercial documentation is to be transparent, available at all times and to be open for review by both Parties whenever
requested.

 

Article
XV. CONFIDENTIALITY

 

All Confidential Information disclosed by one Party to the other pursuant
to this Agreement will be treated as strictly confidential, and will not be disclosed to anyone except the agents, employees and representatives
of the Parties, and then only on a “need-to-know” basis for the purposes of fulfilling a Party’s role and responsibilities
hereunder. Anyone to whom such a disclosure is made shall be subject to confidentiality restrictions to the Party receiving such Confidential
Information that is no less stringent than that between the Parties hereto. Neither Party will use the Confidential Information of the
other for any purpose other than as set out in this Agreement, and only in compliance with its obligations in the Joint Venture. A Party’s
obligation of confidentiality hereunder is for a period of five (5) years after the expiry or termination of this Agreement or any subsequent
agreement that supersedes or replaces it.

 

Article
XVI. GOVERNING LAW

 

The interpretation and construction of this Agreement shall be governed
by the laws of the Province of Ontario, excluding any conflicts or choice of law rule or principle that might otherwise refer interpretation
or construction of this Agreement to the substantive law of another jurisdiction.

 

Article
XVII. PRESS RELEASES

 

Any press release pertaining to the JV SERVICE or this Agreement is
subject to mutual approval of the Parties, which shall not be unreasonably withheld.

 

Article
XVIII. SEVERABILITY; ENFORCEABILITY

 

If, for any reason, any part of this Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, then such adjudication shall not, to the extent feasible, affect or impair,
in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall
remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part.

 

Article
XIX. INSURANCE & LIABILITY

 

Section
19.01. INSURANCE

 

JV SERVICE/BCNI/Immusafe Labs Inc., as the case may be, will procure
such insurance e.g., commercial general liability insurance .Once the JV/Immusafe Labs Inc. is profitable and is operating in a clinical
setting, then product liability, eventual clinical trials, public liability insurance will be evaluated by both partners for suitability
and cost vs. utility.

 

    -11-

     

    

 

Any insurance will be placed with a reputable and financially secure
insurance carrier and will:

 

		(a)	include PROMIS and BCNI, its officers, directors and employees as additional insured;

 

		(b)	provide coverage regarding all relevant activities contemplated under this Agreement;

 

		(c)	include a waiver of subrogation against PROMIS and BCNI, and a severability of interest and cross-liability clauses;

 

		(d)	provide that the insurer will endeavour to notify PROMIS and BCNI at least 30 days prior to the cancellation of the policy;

 

		(e)	JV SERVICE/BCNI/Immusafe Labs Inc., on request, will provide to PROMIS certificates of insurance evidencing the insurance coverages
(and any renewals) of the JV SERVICE/BCNI/Immusafe Labs Inc., and its subcontractors in respect of the activities of this Agreement;

 

Section
19.02. DISCLAIMERS

 

		(a)	‘As Is’ Basis: The Licensed Technology is provided by PROMIS and BCNI on an ‘as is’ basis, and neither
BCNI or PROMIS makes no warranties, representations or conditions, express or implied, of any nature, and disclaims all warranties, representations
or conditions, for the Licensed Technology or Confidential Information including, without limitation, merchantability, quality, fitness
for any or a particular purpose, commercial utility or practical purpose, latent or other defects, infringement or non-infringement of
Patents or other third party rights.

 

		(b)	Disclaimer of Statutorily Implied Warranties: No legal or equitable warranties or conditions implied by law or convention under
any domestic, foreign or international legal regime, or from a course of dealing or usage of trade, shall apply to this Agreement. The
JV SERVICE/Immusafe Labs Inc. and BCNI, as the case may be, acknowledges this disclaimer and is estopped from relying on any such representations,
warranties or conditions against PROMIS. The JV SERVICE/Immusafe Labs Inc. and ProMIS, as the case may be, acknowledges this disclaimer
and is estopped from relying on any such representations, warranties or conditions against BCNI.

 

		(c)	Licensee Shall Obtain Regulatory Permissions: JV SERVICE/Immusafe Labs Inc., or BCNI, as the case may be, shall obtain any
authorizations, permits, certificates or other regulatory permissions which may be required in order for JV SERVICE/Immusafe Labs Inc.
or BCNI as the case may be, to legally carry out all of its activities under this Agreement, including but not limited to Commercialization.
Any costs associated with the regulatory permissions should be carried by the JV service/Immusafe Labs Inc.

 

    -12-

     

    

 

Article
XX. ENTIRE AGREEMENT

 

This Agreement together with any Appendices or attachments, reflects
the entire agreement between the Parties with respect to the subject matter hereof and supersedes all other agreements between the Parties
concerning such subject matter.

 

Article
XXI. MODIFICATIONS.

 

No amendment, modification or supplement of any provision of the Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer or director of each party. No provision of
the Agreement shall be waived by any act, omission or knowledge of any party or its agents or employees except by an instrument in writing
expressly waiving such provision and signed by a duly authorized officer or director of the waiving party.

 

Article
XXII. COUNTERPARTS.

 

The Agreement may be executed in any number of counterparts. A signed
Agreement received by a Party hereto via email will be deemed an original, and binding upon the Party who signed it.

 

Article
XXIII. INDEPENDENT CONTRACTORS.

 

The relationship between PROMIS and BCNI created herein is one of independent
contractors and neither party shall have the power or authority to bind or obligate the other. Nothing in this Agreement shall be interpreted
to create a partnership between the Parties.

 

Article
XXIV. TIME.

 

Time is of the essence in the performance of obligations of this Agreement.

 

Article
XXV. NOTICES

 

Any notice to be given under this Agreement must be in writing and
delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its address given below, or at any address such Party has previously
designated by prior written notice to the other.

 

If to BCNI, notices must be addressed to:

 

BC Neuroimmunology Lab Inc.

Attn. Dr. Hans B Frykman

UBC Hospital

S157 - 2211 Wesbrook Mall

Vancouver BC V6T 2B5

 

If to PROMIS, notices must be addressed to: ProMIS Neurosciences, Inc.

 

Attn. Dr. Elliot Goldstein

1920 Yonge St., suite 200,

Toronto, Ont. M4S 3E2

 

    -13-

     

    

 

In the event of a change of notice address, recipient or both, a Party
shall provide the other Party written notice setting forth the new address and/or recipient, as appropriate

 

Article
XXVI. TERM AND TERMINATION

 

Section
26.01. Term

 

This Agreement shall come into effect on the Effective Date first written
above and shall endure until it is terminated on one of the following possible grounds.

 

Section
26.02. Termination

 

This Agreement may be terminated: (i) by mutual agreement of the Parties;
(ii) for material breach by one of the Parties hereto of its respective obligations under this Agreement; (iii) if the Parties enter into
Definitive Agreements superseding or replacing this Agreement or (iv) if JV SERVICE is wound up, acquired by or merged with another entity,
or otherwise ceases to exist or to do business as contemplated herein.

 

Section
26.03. Notice of Termination

 

The Party seeking to terminate this Agreement shall provide written
notice to the other Party, such written notice to specify in reasonable detail the reasons for termination. Any termination based on clause
(ii) above, namely material breach, shall provide at least 90 Business Days for the breaching party to cure the material breach before
such termination is deemed effective.

 

Section
26.04. Effects of Termination

 

If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by ProMIS in this Agreement shall be terminated automatically and all rights
shall revert to PROMIS, unless PROMIS agrees, in writing, in its exclusive judgement and discretion to extend the time period for (ii)
above, or to modify this Agreement to allow for its continuance

 

If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by BCNI in this Agreement shall be terminated automatically and all rights shall
revert to BCNI, unless BCNI agrees, in writing, in its exclusive judgement and discretion to extend the time period for (ii) above, or
to modify this Agreement to allow for its continuance.

 

Article
XXVII. ASSIGNMENT

 

This Agreement may not be assigned by a Party without the prior
written consent of the other Party except in connection with the sale or transfer of all or substantially all of the assets of such
Party relevant to the subject matter hereof, or in connection with a corporate reorganization, provided that the other Party is
notified of the assignment and the assignee expressly undertakes in writing to be bound by all of the provisions of this
Agreement.

 

    -14-

     

    

 

IN WITNESS WHEREOF, the Parties have executed this Agreement
by their respective, duly authorized representatives as of the date first written above.

 

	ProMIS Neurosciences Inc.	BC Neuroimmunology Inc
	 	 
	 	 
	/s/ Elliot Goldstein	/s/ Hans Frykman
	NAME:	Elliot Goldstein, MD	NAME:	Dr. Hans Frykman
	TITLE:	President & CEO	TITLE	CEO

 

    -15-

     

    

 

APPENDIX A 

 

LICENSED TECHNOLOGY: PATENTS AND APPLICATIONS

 

ProMIS

 

[LIST OF RELEVANT ProMIS PATENTS AND APPLICATIONS]

 

BCNI

 

[LIST OF RELEVANT BCNI PATENTS AND APPLICATIONS]Exhibit 10.2

 

Certain identified information has been excluded from the exhibit
pursuant to Item 601(a)(6) of Regulation S-K due to personal privacy concerns or pursuant to Item 601(b)(10)(iv) because it is both not
material and is the type of information that the registrant treats as private or confidential. Redacted information is indicated by:
[***]

 

JOINT VENTURE AGREEMENT

PROMIS - BCNI

STAGE ONE: SERVICES

 

This Joint Venture Agreement ( “AGREEMENT”) is entered
into effective July 8, 2020 (the “Effective Date”), by and between ProMIS Neurosciences, Inc., a Canadian corporation with
an address at 1920 Yonge Street, Toronto, ON, M4S 3E2 Canada (“PROMIS”), and BC Neuroimmunology Lab Inc (BCNI)
an accredited, CAP certified diagnostic lab in British Columbia, with an address at UBC Hospital, S157-2211 Wesbrook Mall, Vancouver BC
V6T 2B5 (“BCNI”).

 

RECITALS

 

Whereas ProMIS is a publicly traded (TSX) biotech company focused primarily
on the field of neurodegenerative diseases including Alzheimer’s Disease and dementia, with a proprietary technology platform that
has created a portfolio of patented or patent pending antibodies and peptide antigens, which can be used as both therapeutics (antibodies,
vaccines, gene therapy) and as reagents in proprietary diagnostic assays.; and

 

Whereas BC Neuroimmunology Lab Inc. (BCNI) is a private full service
clinical neuroimmunology lab located in the University of British Columbia (Vancouver) hospital. BCNI is accredited by both the College
of American Pathologists (CAP) and Diagnostic accreditation program (DAP) at the College of Physicians and Surgeons of BC (CPSBC) following
the ISO15189 guidelines. BCNI is the North American reference center for six high complexity serological immunoassays. BCNI has extensive
experience and expertise in Surface Plasmon Resonance (SPR), live and fixed cell-based assays, radio immunoprecipitation assays, ELISA,
immunoblot, and immunohistochemistry assays in a clinical assay setting, servicing the neurology community in North America and Worldwide.

 

and

 

Whereas PROMIS and BCNI wish to enter into a joint venture business
arrangement to provide the services of neurodegenerative disease screening, diagnostics and monitoring, using proprietary blood-based
biomarkers (the “JV SERVICE”).

 

NOW, THEREFORE, in consideration of the mutual covenants and premises
set forth herein, the Parties agree as follows

 

Article
I. DEFINITIONS

 

In this Agreement, unless the context indicates otherwise, the words
and expressions set out below shall have the meanings assigned to them and cognate expressions shall have a corresponding meaning, namely:

 

    

    

    

 

“Neurodegenerative diseases”

 

These diseases include but are not limited to Alzheimer’s disease,
Parkinson disease, ALS, FTD, traumatic or insidious brain injury; They do not include traditional neuroimmunology diseases such as Myasthenia
Gravis, NMOSD, Guillain Barre syndrome and other nodal and paranodal diseases, autoimmune encephalitis and paraneoplastic diseases.

 

“Agreement” means this Service Joint Venture Agreement,
together with any validly executed amendments, schedules and appendices.

 

“Applicable Law” means, as to any person, any statute,
law, rule, regulation, administrative guidance, directive, treaty, judgment, order, decree or injunction of any governmental authority
that is applicable to or binding upon such person or any of its properties.

 

“Background Intellectual Property” means any Intellectual
Property excluding Foreground Intellectual Property owned or controlled by either Party prior to commencement of or independently from
the JV SERVICES, and which the owning Party contributes or uses in the course of performing the JV SERVICE

 

“Commercialize” or “Commercialization” includes
the development, distribution, sale, license, transfer or any other venture through which the JV SERVICE or a Party seeks to promote,
market, sell, distribute, manufacture or develop the JV SERVICES, or having any of the foregoing done on its behalf.

 

“Confidential Information” means any information
disclosed by one Party to the other that is not publicly available information, and which is either identified as confidential at the
time of disclosure or which would reasonably be considered to be confidential by its nature or the context of disclosure, including without
limitation Background Intellectual Property disclosed by one Party to the other for use in the JV SERVICES/LICENSED SERVICES and identified
as confidential before or at the time of disclosure, any business information pertaining to a Party or its products or services, and any
products, processes, samples, biological or proprietary materials provided or disclosed pursuant to this Agreement

 

“Definitive Agreements” means such agreements as
may be necessary to set up the JV SERVICE and/or the Newco and complete its organization as contemplated herein.

 

“Field” means (i) the production and use of biomarker
assays for the screening, diagnosis and monitoring of neurodegenerative disease, and/or (ii) the commercialization of such biomarker assays
for the diagnosis and monitoring of Alzheimer’s Disease as a service to third parties.

 

“Foreground Intellectual Property” means any Intellectual
Property which is generated or first reduced to practice by either Party directly as a result of the work undertaken in accordance with
this Agreement, and which is relevant to the JV SERVICE and the Licensed Services/Licensed Technology.

 

“Improvement(s)” means any modification, development,
alteration, derivative or technical advance in or relating to the Licensed Technology/Licensed Services which cannot be used or practiced
without infringing the Background Intellectual Property Rights.

 

    -2-

    

    

 

‘Intellectual Property Rights’ means any and all
existing and future legal protection recognized by law (whether by statute, in equity, at common law or otherwise) anywhere in the world
in respect of the Licensed Technology and Licensed Services, including without limitation trade secret and confidential information protection,
Know-How, patents, Patents, copyright and copyright registration, industrial design registration and trade-marks and trade-mark registrations
and other registrations or grants of rights analogous thereto.

 

“Joint Venture” means the business arrangement between
the Parties as described in this Agreement, including the JV SERVICE and a planned Newco.

 

“JV SERVICE” means the service of providing lab
services and blood-based assays for Alzheimer’s Disease diagnosis and monitoring to the scientific, medical and pharmaceutical communities,
using Licensed Services and/or Licensed Technology, as well as other technology that may be available to the Joint Venture;

 

“Know-how” means all the research results, data,
reports, dossiers, technical information, expertise, practice, experience, skill and technical knowledge of industrial significance and
all unpatented trade secrets, manufacturing methods and technologies, SOP’s, QA and QC procedures, designs, processes, techniques,
information, drawings and specifications, and technical data acquired by and in the possession of PROMIS, BCNI, or JV SERVICE, and not
in the public domain, and relating to the Licensed Technology or Licensed Services.

 

‘Licensed Service(s)’ means any assay that is/are
derived in whole or in part by the use of any of the Intellectual Property Rights and/or the Licensed Technology, of either Party, including
without limitation PROMIS proprietary antibodies and antigen peptides for blood-based biomarker assays for the screening, diagnosis and
monitoring of neurodegenerative diseases, as listed in this Agreement or added to it by validly executed amendment.

 

“Licensed Technology” means the platforms owned
by PROMIS and/or BCNI that will be used by the JV SERVICE and NEWCO to develop and provide the neurodegenerative screening, diagnostics
and monitoring services, and any Intellectual Property Rights therein or thereto, necessary or useful to develop, manufacture or Commercialize
the Licensed Service(s) within the Field in the Territory. The Licensed Technology includes, without limitation, the Technology and Patents
listed on Appendix A.

 

“Net Revenue” shall mean Revenue, less such of the
following items but only insofar as they are separately itemized on the invoice and actually paid or allowed: (i) discounts or rebates
(ii) credits or allowances upon claims or returns, (iii) taxes or other government charges, and (iv) shipping and insurance costs, brokerage
and customs duties.

 

“Newco” means a corporate entity which is planned
in the near future to be established by the Parties to conduct the business and operations of the JV SERVICE.

 

“Patents” means those patents and patent applications
listed in, or which may be added to, Appendix A from time to time hereunder, any divisional applications, continuation applications, continuation-in-part
applications, reissues, or re-examinations claiming priority to either of these, and all patent applications and patents corresponding
to or derived from any of the above.

 

    -3-

    

    

 

“Party” means PROMIS or BCNI, if individually referred
to, and “Parties” shall mean PROMIS and BCNI together.

 

“Revenue” means the gross amount of consideration
received by BCNI, JV SERVICE or NEWCO, as the case may be, in respect of the provision of the JV SERVICE, including money, goods and services,
royalties, milestone payments and any other consideration that may be received from a Sale of any of the services provided by the JV SERVICE
or Newco.

 

“Sale” means any sale, lease, use and services associated
with provision of a JV SERVICE, Licensed Service or service relating to a Licensed Service and “Sales” and “Sell”
have corresponding meanings;

 

“Technology” includes inventions, discoveries, designs,
ideas, works, creations, developments, algorithms, drawings, compilations of information, analyses experiments, data, reports, Know-How,
formulae, methods, processes, techniques, moulds, prototypes, products, samples, equipment, tools, machines, software and documentation
therefore, flow-charts, specifications and source code listings; and includes any modifications or improvements thereto, whether patentable
or not.

 

“Term” is defined in Section 27.

 

“Territory” is defined in Section 14.

 

Article
II. PURPOSE OF THE JOINT VENTURE

 

Section
2.01.        STAGE ONE

 

		(a)	The purpose of this Joint Venture is to establish, fund and operate the JV SERVICE to provide CSF and blood-based Alzheimer’s
Disease and other neurodegenerative disease screening, diagnostics and monitoring to the scientific, medical and pharmaceutical communities,
through a combination of both Parties’ expertise, intellectual property and relevant assets, including without limitation the Licensed
Technology and Licensed Service(s).

 

		(b)	Stage One of the Joint Venture will focus on building the foundation for a revenue base providing diagnostic services, (“JV
SERVICE”) initially for NfL and pTau181 blood-based assays.

 

		(c)	During Stage One, opportunities for an expanded assay portfolio will be explored by the Parties, including the development of proprietary
assays using ProMIS’ proprietary reagents, in addition to identification and evaluation of potential third-party assays to offer
as part of the JV SERVICE.

 

		(d)	The parties will jointly evaluate the feasibility of developing equally accurate or superior assays for NfL and pTau181 on SPR and
other high throughput platforms.

 

    -4-

    

    

 

Section 2.02.        Stage
Two

 

		(a)	The parties plan to expand the scope of the Joint Venture in the near future (by October/November 2020) and enter into a Stage Two
of the arrangement, and, will enter into such further agreements as may be required at the time, including but not limited to: governance
and decision making, revenue recognition, reporting requirements, creating a jointly owned corporation to employ and compensate key staff.
The parties agree that the general principles contained in this Agreement, including roles, economic shares, and the Field will be maintained
in future additional or updated agreements.

 

		(b)	Stage Two will focus on expanding the revenue base of diagnostic services in the Field. The specific activities will be contingent
on results and market developments during Stage One, but will likely include:

 

		(i)	Expanding diagnostic capacity at BCNI for the JV SERVICE, with equipment, space, and personnel (this expansion can precede the revenue
stage, as outlined above, by mutual consent);

 

		(ii)	Building or acquiring a USA-based lab facility in 2021. The new USA lab is anticipated to be owned and operated by the Newco, likely
via a USA C corporation fully owned by the Newco. BCNI will provide an exclusive license of best in class proprietary and unique neuroimmunology
assays to this lab for sole use on the USA market, assuring strong financial stability to the USA lab. Once the USA lab is operating,
the service at BCNI will focus on the Canada market together with research and development, while the USA lab will service the USA market
only;

 

		(iii)	Continuing to build the portfolio of assays offered, both proprietary assays and third-party assays;

 

		(iv)	Pursuing sales and marketing approaches to expand the customer base and revenue base in North America;

 

		(v)	Conducting R&D, clinical validation, and pursuing regulatory approvals required to develop revenue; and

 

		(vi)	Pursuing collaborations with diagnostic labs outside of North America, or potentially licensing/partnering deals with platform companies
or global diagnostics players, to develop revenue beyond what the Joint Venture can realize in laboratories it operates in North America.

 

Article
III. BACKGROUND

 

Section
3.01.     Experience of the Parties

 

Both Parties bring significant experience with respect to development
and provision of diagnostic assay services to this Joint Venture.

 

    -5-

    

    

 

		(a)	Specifically, PROMIS possesses expertise in neurodegenerative diseases including Alzheimer’s Disease and dementia, together
with proprietary technology platforms to predict better specificity for diagnostic purposes. ProMIS owns a portfolio of patented or patent
pending antibodies and peptide antigens which are useful for the purpose of diagnostics. ProMIS is also well-connected in the scientific,
medical and pharmaceutical communities.

 

		(b)	BCNI is an accredited, DAP and CAP certified diagnostic lab in British Columbia, with expertise and experience in validating and accrediting
assays with DAP and College of American Pathologists. BCNI also has experience in marketing and sales of such assays to the neurologist
community, larger labs with vast distribution, and pharmaceutical companies.

 

Article
IV. CONTRIBUTIONS OF THE PARTIES.

 

The Parties will faithfully dedicate reasonable commercial and technological
resources to help the business of the JV SERVICE succeed.

 

Section
4.01.        Joint Contributions

 

		(a)	The parties will fund (by loan) equally operating costs associated with Stage One activities, expected not to exceed CAD $[***] per
month. Therefore, each Party will contribute CAD $[***] each month following until the JV SERVICE is cashflow positive

 

		(b)	Each Party will lend the JV SERVICE CAD $[***] by no later than September 15,2020 for the purchase of a Quanterix SIMOA HD-X.

 

		(c)	Any additional capital expenditures, or major expense projects (such as a validation clinical trial) will require the consent of both
parties and will be funded 50/50 unless otherwise agreed by both parties.

 

		(d)	The Newco, a new BC registered corporation is planned to be established in the near future to provide the JV SERVICE, and additional
non-voting shares in the Newco can be sold to familiar and supportive 3rd parties such as ProMIS shareholders and friends and family of
the founders up to value of USD $[***] and at a pre-money value agreeable to BCNI and ProMIS.

 

Section
4.02.         Individual Contributions

 

		(a)	In addition, PROMIS’s contribution to the JV SERVICE will include:

 

		(i)	Provide at cost proprietary antigens and peptides which can be used as reagents in proprietary diagnostic assays for the JV SERVICE;

 

		(ii)	Share expertise in neurodegenerative diseases including Alzheimer’s Disease and dementia;

 

    -6-

    

    

 

		(iii)	License to the JV SERVICE its proprietary technology platforms (“Licensed Technology”) to predict better specificity for
diagnostic purposes;

 

		(iv)	Apply its existing proprietary reagents to assay development and will continue develop and contribute new proprietary reagents.

 

		(v)	Regulatory and clinical development support;

 

		(vi)	Take the lead on market related activities, including outreach to KOLs, physician customers, CROs, global distribution partners, other
revenue development etc. and will together with BCNI, assign or hire staff in the Newco to lead that effort

 

		(vii)	Continuous scientific, technological, marketing, strategic, updating process development, and support.

 

		(b)	In addition, BCNI’s contribution to the JV SERVICE will include:

 

		(i)	General management of the JV SERVICE: Dr. Hans Frykman of BCNI will serve as lab director at the Vancouver site, with deferred payment
until the JV/ Newco is cashflow positive and can carry his salary. These payments to Dr. Hans B Frykman Medical Corp will supersede paying
shareholders at that time. BCNI will initially hire and manage capable staff, and will manage the operations of the accredited laboratories.
This staff will be paid at cost by JV/Newco, a CEO of the Newco will be jointly appointed by BCNI and ProMIS;

 

		(ii)	Perform all Neurodegenerative assays at cost, calculated by an internal standard method normally used;

 

		(iii)	Provide guidance in marketing and sales of the assays to the hospital labs, neurologist community in North America, test distributors,
larger labs with vast distribution, and pharmaceutical companies; Will together with ProMIS assign and hire staff in Newco to lead this
effort

 

		(iv)	Contribute (Dr. Hans Frykman at deferred cost as described above and other staff at normal salary cost) its expertise and experience
in validating and accrediting the assays with DAP and College of American Pathologists; with aim to also acquire Health Canada and FDA
approvals. Particulary for proprietary assays.

 

		(v)	Assume primary responsibility for dealing with health and regulatory authorities in the Territory, including, without limitation,
presentation, submission and approval of any necessary marketing/regulatory authorizations for the JV SERVICE and Licensed Services; Will
together with ProMIS hire staff for this purpose

 

    -7-

    

    

 

		(vi)	In the case of any clinical trial sponsored by ProMIS, BCNI/JV SERVICE/Newco will supply the NfL and pTau181 assays at cost, based
on the jointly acquired Quanterix machine and/or the mutually developed SPR assays. This discount will survive the termination of the
Joint Venture, as long as the Quanterix or SPR assays are operational and available at BCNI/JV SERVICE/Newco in exchange for any funds
owed to ProMIS for purchase of Quanterix or SPR equipment.

 

Article
V. ALLOCATION AND DISTRIBUTION OF REVENUES 

 

Section
5.01.        Ownership

 

PROMIS and BCNI (and related companies) shall each own 50% of the JV
SERVICE and the Newco is planned to be established to provide the JV SERVICE.

 

Section
5.02.        Revenue

 

Net Revenue from the JV SERVICE will be distributed to each Party equally,
except as otherwise specified in this Agreement. JV SERVICE revenue will be recognized by BCNI/JV SERVICE/Newco. Direct expenses, rental
expenses, staff expenses, and capital expenses associated with that revenue will be covered by that revenue to the extent possible before
any revenue is distributed.

 

Section
5.03.        Working Capital, Operating Losses

 

Working capital needs, or operating losses will be covered equally
by both parties.

 

Section
5.04.        Investment Decisions

 

Investment decisions will require mutual consent and will be funded
equally, which funding may come from current revenue and operating profit.

 

Section
5.05.        Surplus, Operating Cash Flow

 

Cash surpluses, operating cash flow after paying current expenses and
not allocated to capital investment by mutual consent, will be distributed equally (50/50 split) to both parties on a time schedule to
be agreed - not more frequent than monthly, not less frequent than quarterly. (With the exception of cash surpluses generated from partnerships
or labs outside of North America, see below)

 

Section
5.06.        Additional Revenue

 

Notwithstanding the foregoing, however, Net Revenue to the JV
SERVICE/Newco which comes from sources other than labs operated by the JV SERVICE in North America will be disbursed equally (50/50
split) for revenue derived from assays not incorporating ProMIS proprietary reagents. For revenue derived from collaborations with
labs in regions of the world other than North America, who choose to sell proprietary assays developed by the JV SERVICE/Newco, only
if promis proprietary knowledge, reagents/ chemicals were used as a deciding factor to improve accuracy of assay, the disbursement
will be 80% to ProMIS and 20% to BCNI (80/20 split). Prior to finalizing any such deal both parties will confirm that this economic
split applies and is dependent on the relative contribution of each party into the Intellectual Property Rights developed for such
JV SERVICES.

 

    -8-

    

    

 

Article
VI. JV Meetings

 

		(a)	JV meetings will be held weekly. Minutes of the meetings will be maintained on file.

 

		(b)	Either ProMIS or BCNI can call a special meeting to resolve urgent issues that require a vote and that cannot wait for the next regularly
scheduled meeting. When calling a special meeting, the other party must be provided with reasonable notice. Where a special meeting has
been called, the meeting will be restricted to the specific purpose for which the meeting was called.

 

		(c)	All meetings will be held at a time and in a location that is reasonable, convenient and practical considering the situation of BCNI
and ProMIS.

 

Article
VII. NAME

 

The name of JV SERVICE and BC “Newco” shall be as mutually
agreed by PROMIS and BCNI.

 

Article
VIII. PRINCIPAL PLACE OF BUSINESS

 

The principal place of business of JV SERVICE/Newco shall be initially
at the BCNI premises in Vancouver, BC, unless PROMIS and BCNI later decide otherwise. The Newco will be a BC corporation.

 

Article
IX. INTELLECTUAL PROPERTY

 

Section
9.01.        Ownership Of Intellectual Property Rights

 

		(a)	Background Intellectual Property All Background Intellectual Property including any proprietary materials provided and used
in connection with the JV SERVICE and/or the Licensed Services shall remain the property of the Party introducing the same. Neither Party
will make any representation or do any act which may be taken to indicate that it has any right, title or interest in or to the ownership
or use of any of the Background Intellectual Property of the other party except under the terms of this Agreement. Each Party acknowledges
and confirms that nothing contained in this Agreement shall give it any right, title or interest in or to the Background Intellectual
Property of the other Party save as granted by this Agreement. The Parties agree that any Improvements to a Party’s Background Intellectual
Property arising from the Joint Venture will be deemed to form part of that Party’s Background Intellectual Property.

 

    -9-

    

    

 

		(b)	Foreground Intellectual Property.

 

		(i)	Each Party shall own any Foreground Intellectual Property developed solely by it, and shall grant to the JV SERVICE a royalty-free,
perpetual non-exclusive license to such Foreground Intellectual Property that is necessary or useful to the JV SERVICE. Such license shall
be transferable to any Newco established by the Parties to operate the JV SERVICE. The Party owning such Foreground Intellectual Property
shall have the responsibility of registering, maintaining and enforcing any protection for such Foreground Intellectual Property.

 

		(ii)	Any Foreground Intellectual Property jointly developed in the JV SERVICE prior to the establishment of any Newco shall be owned jointly
by the Parties, with the intention that such ownership shall be transferred to any Newco which is established by the Parties to operate
the business of the JV SERVICES. Any IP developed in the Newco will the owned by the Newco. In the interim, the Parties shall be jointly
responsible for registering, maintaining and enforcing any protection for such Foreground Intellectual Property, and shall bear the costs
equally.

 

Article
X. LICENSE

 

The JV SERVICE will have the non-exclusive license to use the Licensed
Technology to make, market and sell in the Territory the Licensed Services contemplated by this Agreement. Each Party hereby grants to
the JV SERVICE a royalty-based, non-exclusive licence for the duration of the Agreement to use its Background Intellectual Property for
the sole purpose of providing the Licensed Services.

 

Article
XI. REPORTS & RECORDS

 

Section
11.01. Reports and Other Deliveries.

 

Within thirty (30) days of the receipt of Revenue in respect of any
services provided by the JV SERVICE, the JV SERVICE shall provide to PROMIS and

 

BCNI a written report detailing any Revenue received in respect of
the JV SERVICE from any source and the amount thereof, and calculating the payment due to each Party in respect thereof.

 

Section
11.02. Books and Records.

 

The JV SERVICE shall keep complete, true and
accurate books of account containing all particulars that may be necessary for the purpose of showing the amounts payable to PROMIS
and BCNI. Such books of account shall normally be kept at the JV SERVICE’S principal place of business. Upon reasonable notice
to the JV SERVICE during regular working hours, all applicable books and the supporting data shall be available for inspection by
PROMIS or BCNI or their agents, on a confidential basis, at all reasonable times for up to five years following the end of the
calendar year to which they pertain, for the purpose of verifying such JV SERVICE accounting of payments and compliance in other
respects with this Agreement. If such inspection determines that any amount that should have been paid has not been paid, the JV
SERVICE shall promptly pay such amount. If an additional payment is 5% or greater than the amount previously reported and paid for
in the relevant period, then the JV SERVICE shall pay PROMIS/BCNI any such deficiency as well as the expenses of the examination.
The cost of accounting services (initially at BCNI) shall be carried by the JV at cost.

 

    -10-

    

    

 

Article
XII. NO VIOLATION OF AGREEMENT DUE TO OTHER ACTIVITIES 

 

Subject to any exclusivity provisions set forth in this Agreement,
BCNI acknowledges that PROMIS is involved in research and development projects and agreements which involve the development, manufacturing
and commercialization of biologic products and that this does not infringe this Agreement between BCNI and PROMIS. PROMIS acknowledge
that BCNI is involved in the research and development, manufacturing and commercialization of diagnostic products primarily but not exclusively
in the field of Neuroimmunology and that this does not infringe this agreement between BCNI and PROMIS.

 

Article
XIII. STAGE ONE GOVERNANCE AND MANAGEMENT OF JV SERVICE

 

Section
13.01. Lab Director

 

		(a)	In Stage One, Hans Frykman of BCNI will serve as lab director at the Vancouver site, or BCNI will initially hire and manage capable
staff, and will manage the operations of the accredited laboratories in Canada. Dr. Hans Frykman, will defer his fees for service until
the JV is cash flow positive and when it can carry such cost without forsaking future opportunities. His professional fees, paid to Dr.
Hans B Frykman Medical Corp., will at that time, have preference to paying shareholders or the JV partners.

 

Section
13.02. Key Decisions

 

		(a)	In Stage One, the Parties will discuss all material decisions affecting the operations, expenditures and commitments of the JV SERVICE
/ newco, and PROMIS, BCNI or its designates shall not make any key decisions concerning such operations, expenditures and commitments
without the prior written consent of PROMIS and BCNI.

 

Article
XIV. TERRITORY

 

The Territory in which the JV SERVICE will operate, and for which the
licenses hereunder are granted is Worldwide

 

Article
XV. TRANSPARENCY

 

Subject to applicable confidentiality provisions and Applicable Laws,
all financial and commercial documentation is to be transparent, available at all times and to be open for review by both Parties whenever
requested.

 

    -11-

    

    

 

Article
XVI. CONFIDENTIALITY

 

All Confidential Information disclosed by one Party to the other pursuant
to this Agreement will be treated as strictly confidential, and will not be disclosed to anyone except the agents, employees and representatives
of the Parties, and then only on a “need-to-know” basis for the purposes of fulfilling a Party’s role and responsibilities
hereunder. Anyone to whom such a disclosure is made shall be subject to confidentiality restrictions to the Party receiving such Confidential
Information that is no less stringent than that between the Parties hereto. Neither Party will use the Confidential Information of the
other for any purpose other than as set out in this Agreement, and only in compliance with its obligations in the Joint Venture. A Party’s
obligation of confidentiality hereunder is for a period of five (5) years after the expiry or termination of this Agreement or any subsequent
agreement that supersedes or replaces it.

 

Article
XVII. DUTY OF LOYALTY AND NON-COMPETE

 

Neither BCNI or ProMIS will engage in any business, venture or transaction,
whether directly or indirectly, that might be competitive with the business of the Venture or that would be in direct conflict of interest
to the Venture. Any potential conflicts of interest will be deemed an Involuntary Withdrawal.

 

A dissociated or withdrawing Member will not carry on a similar business
to the business of the Venture within any established or contemplated market regions of the Venture for a period of at least one year
from the date of dissociation or withdrawal.

 

Article
XVIII. GOVERNING LAW

 

The interpretation and construction of this Agreement shall be governed
by the laws of the Province of British Columbia, excluding any conflicts or choice of law rule or principle that might otherwise refer
interpretation or construction of this Agreement to the substantive law of another jurisdiction.

 

Article
XIX. PRESS RELEASES

 

Any press release pertaining to the JV SERVICE or this Agreement is
subject to mutual approval of the Parties. Once Newco is funded and operational, a certain amount of secrecy to operations is warranted
to better manage competition.

 

Article
XX. SEVERABILITY; ENFORCEABILITY

 

If, for any reason, any part of this Agreement is adjudicated invalid,
unenforceable or illegal by a court of competent jurisdiction, then such adjudication shall not, to the extent feasible, affect or impair,
in whole or in part, the validity, enforceability or legality of any remaining portions of this Agreement. All remaining portions shall
remain in full force and effect as if the original Agreement had been executed without the invalidated, unenforceable or illegal part.

 

    -12-

    

    

 

Article
XXI. INSURANCE & LIABILITY

 

Section
21.01. INSURANCE

 

JV SERVICE/BCNI/ProMIS/Newco, as the case may be, will procure such
insurance e.g., commercial general liability insurance, paid by the JV/Newco. Once the JV/Newco is profitable and is operating in a clinical
setting, then product liability, clinical trials, public liability insurance will be evaluated by both partners for suitability and cost
vs. utility.

 

Any insurance will be placed with a reputable and financially secure
insurance carrier and will:

 

		(a)	include PROMIS and BCNI, its officers, directors and employees as additional insured;

 

		(b)	provide coverage regarding all relevant activities contemplated under this Agreement;

 

		(c)	include a waiver of subrogation against PROMIS and BCNI, and a severability of interest and cross-liability clauses;

 

		(d)	provide that the insurer will endeavour to notify PROMIS and BCNI at least 30 days prior to the cancellation of the policy;

 

		(e)	JV SERVICE/Newco, on request, will provide to PROMIS and BCNI certificates of insurance evidencing the insurance coverages (and any
renewals) of the JV SERVICE/Newco, and its subcontractors in respect of the activities of this Agreement;

 

Section
21.02. DISCLAIMERS

 

		(a)	‘As Is’ Basis: The Licensed Technology is provided by PROMIS and BCNI on an ‘as is’ basis, and neither
BCNI or PROMIS makes any warranties, representations or conditions, express or implied, of any nature, and disclaims all warranties, representations
or conditions, for the Licensed Technology or Confidential Information including, without limitation, merchantability, quality, fitness
for any or a particular purpose, commercial utility or practical purpose, latent or other defects, infringement or non-infringement of
Patents or other third party rights.

 

		(b)	Disclaimer of Statutorily Implied Warranties: No legal or equitable warranties or conditions implied by law or convention under
any domestic, foreign or international legal regime, or from a course of dealing or usage of trade, shall apply to this Agreement. The
JV SERVICE/Newco and BCNI, as the case may be, acknowledges this disclaimer and is stopped from relying on any such representations, warranties
or conditions against PROMIS. The JV/Newco and ProMIS acknowledge this disclaimer and is stopped from relying on any such representations,
warranties or conditions against BCNI.

 

    -13-

    

    

 

		(c)	Licensee Shall Obtain Regulatory Permissions: JV SERVICE/Newco, or BCNI and ProMIS, as the case may be, shall obtain any authorizations,
permits, certificates or other regulatory permissions which may be required in order for JV SERVICE/Newco or BCNI and ProMIS as the case
may be, to legally carry out all of its activities under this Agreement, including but not limited to Commercialization.

 

Article
XXII. ENTIRE AGREEMENT

 

This Agreement together with any Appendices or attachments, reflects
the entire agreement between the Parties with respect to the subject matter hereof and supersedes all other agreements between the Parties
concerning such subject matter.

 

Article
XXIII. MODIFICATIONS.

 

No amendment, modification or supplement of any provision of the Agreement
shall be valid or effective unless made in writing and signed by a duly authorized officer or director of each party. No provision of
the Agreement shall be waived by any act, omission or knowledge of any party or its agents or employees except by an instrument in writing
expressly waiving such provision and signed by a duly authorized officer or director of the waiving party.

 

Article
XXIV. COUNTERPARTS.

 

The Agreement may be executed in any number of counterparts. A signed
Agreement received by a Party hereto via email will be deemed an original, and binding upon the Party who signed it.

 

Article
XXV. TIME.

 

Time is of the essence in the performance of obligations of this Agreement.

 

Article
XXVI. NOTICES

 

Any notice to be given under this Agreement must be in writing and
delivered either in person, by any method of mail (postage prepaid) requiring return receipt, or by overnight courier or facsimile confirmed
thereafter by any of the foregoing, to the Party to be notified at its address given below, or at any address such Party has previously
designated by prior written notice to the other.

 

If to BCNI, notices must be addressed to:

 

BC Neuroimmunology Lab Inc.

Attn. Dr. Hans B Frykman

 

C/O MORTON LAW LLP

Corporate & Securities Lawyers

1200-750 W. Pender Street

Vancouver, British Columbia

Canada, V6C 2T8

 

    -14-

    

    

 

If to PROMIS, notices must be addressed to:

 

ProMIS Neurosciences, Inc.

Attn. Dr. Elliot Goldstein

1920 Yonge St, Suite 200

Toronto Ont. M4S 3E2

 

In the event of a change of notice address, recipient or both, a Party
shall provide the other Party written notice setting forth the new address and/or recipient, as appropriate

 

Article
XXVII. TERM AND TERMINATION

 

Section
27.01. Term

 

This Agreement shall come into effect on the Effective Date first written
above and shall endure until it is terminated on one of the following possible grounds.

 

Section
27.02. Termination

 

This Agreement may be terminated: (i) by mutual agreement of the Parties;
(ii) for material breach by one of the Parties hereto of its respective obligations under this Agreement; (iii) if the Parties enter into
Definitive Agreements superseding or replacing this Agreement (for instance, upon entering Stage Two of the Joint Venture); or (iv) if
JV SERVICE is wound up, acquired by or merged with another entity, or otherwise ceases to exist or to do business as contemplated herein.

 

Section
27.03. Notice of Termination

 

The Party seeking to terminate this Agreement shall provide written
notice to the other Party, such written notice to specify in reasonable detail the reasons for termination. Any termination based on clause
(ii) above, namely material breach, shall provide at least 90 Business Days for the breaching party to cure the material breach before
such termination is deemed effective.

 

Section
27.04. Effects of Termination

 

If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by ProMIS or BCNI in this Agreement shall be terminated automatically and all
rights shall revert to PROMIS or BCNI respectively, unless either party agrees, in writing, in its exclusive judgement and discretion
to extend the time period for (ii) above, or to modify this Agreement to allow for its continuance

 

If this Agreement is terminated, all licenses of the Intellectual Property
Rights, Licensed Services and Licensed Technology granted by BCNI in this Agreement shall be terminated automatically and all rights shall
revert to BCNI, unless BCNI agrees, in writing, in its exclusive judgement and discretion to extend the time period for (ii) above, or
to modify this Agreement to allow for its continuance

 

Article
XXVIII. ASSIGNMENT

 

This Agreement may not be assigned by a Party without the prior written
consent of the other Party except in connection with the sale or transfer of all or substantially all of the assets of such Party relevant
to the subject matter hereof, or in connection with a corporate reorganization, provided that the other Party is notified of the assignment
and the assignee expressly undertakes in writing to be bound by all of the provisions of this Agreement.

 

IN WITNESS WHEREOF, the Parties have executed this Agreement
by their respective, duly authorized representatives as of the date first written above.

 

	ProMIS Neurosciences Inc.	BC Neuroimmunology Inc
	 	 
	 	 
	/s/ Elliot Goldstein	/s/ Hans Frykman
	NAME: Elliot Goldstein, MD	NAME: Dr. Hans Frykman
	TITLE:  CEO	TITLE:  CEO

 

    -15-

    

    

 

APPENDIX A

LICENSED TECHNOLOGY: PATENTS AND APPLICATIONS

 

 

ProMIS

 

[LIST OF RELEVANT ProMIS PATENTS AND APPLICATIONS]

 

BCNI

 

[LIST OF RELEVANT BCNI PATENTS AND APPLICATIONS]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]